DOI: 10.1111/sji.13331

#### **ORIGINAL ARTICLE**

## **IgG exacerbates genital chlamydial pathology in females by enhancing pathogenic CD8**<sup>+</sup> **T cell responses**

**Charles W. Armitage<sup>1</sup> | Connor P. O'Meara<sup>[1,2](#page-0-0)</sup> | Emily R. Bryan<sup>1</sup> | Avinash Kollipara[1](#page-0-0)** | **Logan K. Tri[m1](#page-0-0)** | **Danica Hickey[1](#page-0-0)** | **Alison J. Carey[1](#page-0-0)** | **Wilhelmina M. Huston[3](#page-0-1)** | **Gavin Donnelly[4](#page-0-2)** | **Anusch Yazdani[4](#page-0-2)** | **Richard S. Blumberg[5](#page-0-3)** | **Kenneth W. Beagley[1](#page-0-0)**

<span id="page-0-0"></span>1 Centre for Immunology and Infection Control and School of Biomedical Sciences, Queensland University of Technology (QUT), Brisbane, Queensland, Australia

2 Drop Bio Ltd, School of Biotechnology and Biomolecular Sciences (BABS), University of New South Wales, Sydney, New South Wales, Australia

<span id="page-0-1"></span>3 School of Life Sciences, University of Technology (UTS) Sydney, Ultimo, New South Wales, Australia

<span id="page-0-2"></span>4 Queensland Fertility Group (QFG), Brisbane, Queensland, Australia

<span id="page-0-3"></span>5 Division of Gastroenterology, Department of Medicine, Brigham & Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA

#### **Correspondence**

Kenneth W. Beagley, Centre for Immunology and Infection Control and School of Biomedical Sciences, Queensland University of Technology, 300 Herston Road, Herston, QLD 4006, Australia. Email: [k2.beagley@qut.edu.au](mailto:k2.beagley@qut.edu.au)

#### **Funding information**

National Health and Medical Research Council, Grant/Award Number: 1049571

#### **Abstract**

*Chlamydia trachomatis* infections are an important sexually transmitted infection that can lead to inflammation, scarring and hydrosalpinx/infertility. However, infections are commonly clinically asymptomatic and do not receive treatment. The underlying cause of asymptomatic immunopathology remains unknown. Here, we demonstrate that IgG produced during male infection enhanced the incidence of immunopathology and infertility in females. Human endocervical cells expressing the neonatal Fc Receptor (FcRn) increased translocation of human IgG-opsonized *C.trachomatis*. Using total IgG purified from infected male mice, we opsonized *C.muridarum* and then infected female mice, mimicking sexual transmission. Following infection, IgG-opsonized *Chlamydia* was found to transcytose the epithelial barrier in the uterus, where it was phagocytosed by antigen-presenting cells (APCs) and trafficked to the draining lymph nodes. APCs then expanded both  $CD4^+$  and  $CD8^+$  T cell populations and caused significantly more infertility in female mice infected with non-opsonized *Chlamydia*. Enhanced phagocytosis of IgG-opsonized *Chlamydia* significantly increased proinflammatory signalling and T cell proliferation. As IgG is transcytosed by FcRn, we utilized FcRn−/− mice and observed that shedding kinetics of *Chlamydia* were only affected in FcRn−/− mice infected with IgG-opsonized *Chlamydia*. Depletion of CD8<sup>+</sup> T cells in FcRn<sup>-/-</sup> mice lead to a significant reduction in the incidence of infertility. Taken together, these data demonstrate that IgG seroconversion during male infection can amplify female immunopathology, dependent on FcRn transcytosis, APC differentiation and enhanced CD8 T cell responses.

This is an open access article under the terms of the [Creative Commons Attribution](http://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

© 2023 The Authors. *Scandinavian Journal of Immunology* published by John Wiley & Sons Ltd on behalf of The Scandinavian Foundation for Immunology.

# **2 of 15 WILEY-IMMÜNOLOGY ARMITAGE ET AL.**

## **1** | **INTRODUCTION**

Urogenital *Chlamydia trachomatis* infections of the male and female urogenital tracts are the world's leading sexually transmitted bacterial infection with an estimated 127 million new cases each year.<sup>[1](#page-12-0)</sup> Despite widespread public awareness and education, infections continue to rise, quadrupling in the USA in the last two decades, $<sup>2</sup>$  $<sup>2</sup>$  $<sup>2</sup>$  and cost-</sup> ing an estimated US\$ 2 billion per annum.<sup>3</sup> Chlamydial infection is asymptomatic in males (30%-60%) and females (70%-90%) allowing continued dissemination without treatment,<sup>4</sup> likely owing to recurrent infections and the influence of the high allelic variability of human major histocompatibility complexes (MHC).<sup>[5](#page-12-4)</sup> If detected, *Chlamydia* spp. are sensitive to azithromycin and doxycycline antibiotics, but if left untreated acute asymptomatic infection can lead to chronic inflammation and severe sequelae including fallopian tube scarring and occlusion, pelvic inflammatory disease (PID), ectopic pregnancy and infertility[.6](#page-12-5) A widely used model of *C.trachomatis* infection is vaginal infection of female mice with the mousespecific strain *C.muridarum*, which leads to an ascending infection, causing scarring and occlusion of the oviduct (Fallopian tube) and hydrosalpinx (infertility). $7$  Because of the severe sequelae associated with *C.trachomatis* infections, it is widely accepted by the scientific community that there is an urgent requirement for a chlamydial vaccine protecting against pathology.

Antibodies are glycoproteins that are a crucial arm of the adaptive immune response that are produced in response to infection or immunization and are responsible for the immunity obtained from most successful vaccines. Antibodies have multiple functions including not only steric blocking of pathogen attachment to host cells and subsequent invasion, but also enhancing phagocytosis of pathogens by neutrophils, macrophages and dendritic cells. Immunoglobulin G (IgG) is the most abundant immunoglobulin in the blood accounting for 80% of all antibodies, and its concentration in mucosal secretions is dependent on the tissue type. In the female reproductive tract, IgG is found within secretions at a range of 10-467 and 1-200  $\mu$ g mL<sup>-1</sup> in vaginal and cervical/uterine secre-tions respectively.<sup>[8](#page-13-0)</sup> In male ejaculate, there is between 16 and 33 µg mL $^{-1}$  of IgG (depending on the volume)<sup>8</sup> that is secreted by B cells into the circulation and is transcytosed into the mucosal lumen by the epididymis, prostate and accessory organs of the male reproductive tract.<sup>8</sup> Until relatively recently delivery of IgG into the lumen was thought to be mediated by passive flux, it is now suggested that IgG is transported across epithelial cell barriers into the mucosa of mammals by FcRn.<sup>[9,10](#page-13-1)</sup>

The FcRn is expressed throughout the mammalian body on a diverse range of cell lineages, for example, epithelia, endothelia, hepatocytes, podocytes, syncytiotrophoblasts, neutrophils and antigen-presenting cells.<sup>9</sup> FcRn facilitates passive immunity in embryos/neonates via delivery of maternal IgG to the offspring across the placenta and from breastmilk in the neonatal GIT. FcRn is also expressed throughout the body in the gastrointestinal, respiratory and urogenital tracts throughout life. $9,11$ 

Unlike other Fc gamma receptors ( $FcyR<sub>I-IV</sub>$ ) which bind IgG and IgG-bound immune complexes (IgG:IC) near the Fc hinge region of IgG, FcRn reversibly binds IgG:IC and free IgG at the CH2-CH3 domain under acidic conditions (pH5-6.5) and releases IgG at neutral pH (pH7.4), facilitating bidirectional transport of IgG across epithelial cells into and out of the lumen allowing rapid delivery of antigen (or pathogens) to immune cells in the lamina propria. $9,12-14$  As both the male and female reproductive tracts express  $FcRn^{11,15}$  $FcRn^{11,15}$  $FcRn^{11,15}$  and have acidic lumens in the epididymis, $16$  prostate,  $17$  vagina and cervix,  $18$  the potential for FcRn to deliver IgG-bound pathogens to immune cells in the lamina propria is of scientific interest.

*Chlamydia* spp. are obligate intracellular bacteria with a biphasic lifecycle that not only infect mucosal epithelia of the urogenital tracts, but also infect and replicate within leukocytes including neutrophils, macrophages, dendritic cells, modulating how the immune system responds to infection<sup>19,20</sup> but also trafficking infection to unconnected tissues. $^{21}$  Unique from other intracellular bacteria, *Chlamydia* spp. replicate within a parasitophorous vesicle termed the inclusion which secretes proteins that interfere with normal host processes including blocking apoptosis, $^{22}$  inhibiting binding of host endocytic pathway and lysosomal recruitment,<sup>[22](#page-13-8)</sup> as well as MHC-I and MHC-II presentation. $23,24$  Unlike many other intracellular pathogens, the entry of *Chlamydia* into cells can be active or passive.[25](#page-13-10) Like *Chlamydia* spp, the intracellular pathogens *Toxoplasma gondii*, *Mycobacterium bovis* and *Legionella pneumoniae* can infect cells and avoid host cell lysosomal degradation.<sup>[26](#page-13-11)</sup> However, IgG opsonization of these pathogens prior to internalization enhances phagocytosis via binding of IgG to FcγR, which internal-ize IgG:ICs and targets them for lysosomal degradation.<sup>[26](#page-13-11)</sup> Conversely, phagocytosis of IgG-opsonized chlamydial elementary bodies (EBs) enhances uptake but continues to avoid fusion with host cell lysosomes allowing inclu-sion formation and replication.<sup>[12,27,28](#page-13-12)</sup> Similarly, it has been demonstrated that IgG specific for the ubiquitously expressed chlamydial antigen Major Outer Membrane Protein (MOMP) can bind *Chlamydia* EBs and enhance uptake in FcγR and FcRn-dependent mechanisms.<sup>12,27-29</sup> As antibodies are generated in response to chlamydial infection, we sought to determine if IgG from males infected with *Chlamydia* could enhance transcytosis and immunopathology in naïve females following sexual transmission.

## **2** | **MATERIALS AND METHODS**

#### **2.1** | **Ethics statement**

This study was approved by the Queensland University of Technology Animal Ethics Committee (QUT UAEC # 1400000606). All animals were killed by intraperitoneal injection with sodium pentobarbital  $(200 \text{ mg kg}^{-1})$ . Human seminal plasma samples were collected from Queensland Fertility Group (QFG) (Brisbane, QLD, Australia) under accordance with the QFG ethics (02.14) and QUT Human Research Ethics Committee (UHREC #1500000765). Female human sera were collected with approvals from Prince Charles Human Research Ethics Committee (EC2809), Ipswich and West Moreton Health Services District (10-09), Gold Coast Hospital District (200893), Cairns Sexual Health Clinic (HREC/09/QCH/4-554), QUT (1 300000003 and 080000268) and IVF clinics based in Brisbane (UC Health HREC 1314) and Melbourne (HREC number 12099).

#### **2.2** | **Animals**

Mice (BALB/c) were sourced from the Animal Resource Centre (ARC; Canningvale, WA, Australia) at 6weeks of age and given food and water ad libitum. Female BALB/c mFcRn<sup> $-/-$ </sup> mice were backcrossed >10 generations from C57BL/6 mFcRn<sup>-/-</sup> (B6.Fcgrt<sup>tm1Dcr</sup>/DcrJ, #003982) mice sourced from The Jackson Laboratory (Bar Harbour, ME, USA).

#### **2.3** | **Cells and Chlamydia**

Endocervial epithelia (SiHa) (Cat # HTB-35) were purchased from the American Type Cell Culture (ATCC; Manassas, VA, USA). Cells were cultured in RPMI 1640 supplemented with 10% heat-inactivated fetal calf serum,  $100 \mu g m L^{-1}$  streptomycin sulfate,  $50 \mu g m L^{-1}$ gentamycin and 1× Glutamax (ThermoFisher) (RPMI+). *C. muridarum* (Weiss strain) and plasmid-cured *C. muridarum* (Nigg strain;  $CM3.1$ <sup>[39](#page-13-13)</sup> were a generous gift from Dr Catherine O'Connell (UNC Chapel Hill) and were cultured from McCoy cells and purified as previously described.[53](#page-14-0) *C. trachomatis* serovar D (VR-885) and serovar E (VR-348B) were purchased from the ATCC. *Chlamydia* spp. were UV-inactivated for  $2 \times 20$  min, and biotinylated using NHS-biotin (Sigma Aldrich) overnight at  $4^{\circ}$ C in 0.1 mol L<sup>-1</sup> NaHCO<sub>3</sub> pH9 (0.125 mg) NHS-Biotin:1 mg protein). Mouse bone marrow was collected as previously described, $54$  differentiated into macrophages over 6 days using RPMI+ supplemented

with 0.2 μm-filtered 10% L929 cell supernatant or into dendritic cells using media containing  $20 \text{ ng } \text{mL}^{-1}$  recombinant mouse GM-CSF (Lonza, Mt Waverly, VIC, Australia) and  $20 \text{ ng } \text{mL}^{-1}$  recombinant mouse IL-4 (Lonza) as previously described. $54$ 

## **2.4** | **Antibodies**

IgG was purified using Protein G (Genscript, Piscataway, NJ, USA) from the pooled  $(n=10)$  cardiac bleed sera of male BALB/c mice that had previously been infected with 106 inclusion forming units (IFUs) of *C.muridarum* (Weiss) for 10 weeks as previously described. $34$  Naïve mouse IgG (Sigma Aldrich, Castle Hill, NSW, Australia) was used as control IgG. IgG was also purified from human blood using Protein G. Human seminal plasma samples were collected from QFG as part of routine sperm collection for IVF. Purified mouse IgG and human IgG and seminal plasmas were stored at −80°C. Mouse anti-IncA IgG was generated by immunizing mice as previously described.<sup>12</sup> Rabbit anti-mouse FcRn-cytoplasmic tail (mFcRn-CT) and rabbit anti-human FcRn-cytoplasmic tail  $(hFcRn-CT)$  was produced as previously described.<sup>31</sup>

## **2.5** | **Transwells**

Transwells used were 24-well format (Falcon Cat # 353504) with 3  $\mu$ m inserts (Falcon Cat # 353181) seeded with  $5 \times 10^4$ SiHa cells per apical insert and basolateral well (Figure [1A](#page-3-0)) as previously described.<sup>[12](#page-13-12)</sup> Cells were incubated for 6 days with media changes every 2days in both the apical and basal chambers. Cells were cultured in RPMI 1640 supplemented with 10% heat-inactivated fetal calf serum,  $100 \mu g m L^{-1}$  streptomycin sulfate,  $50 \mu g$ mL<sup>-1</sup> gentamycin and 1× Glutamax (ThermoFisher) (RPMI+). Cells in the apical chamber were then infected at MOI 1 with *C.trachomatis* serovar D, which were pre-incubated with antibody. Opsonization for Figure [1A](#page-3-0) was achieved by incubating EBs with purified IgG (as above,  $100 \mu g m L^{-1}$  in HBSS [containing CaCl<sub>2</sub> and  $MgCl<sub>2</sub>$ , Gibco]) on ice for 1h, then EBs were added to apical well at pH6 by buffering the culture media with MES (50mM). Opsonization for Figure [1C](#page-3-0) was achieved by incubating EBs with whole seminal plasma (as above) on ice for 30min, then EBs were added to the apical well.

#### **2.6** | **Intravaginal infections**

Female mice (6-8weeks) were hormonally synchronized by subcutaneous injection of 2.5mg depot medroxyprogesterone (Depo Provera, Pfizer, New York, NY, USA) 1week



<span id="page-3-0"></span>**FIGURE 1** IgG-opsonization enhances chlamydial translocation in human female reproductive epithelial cells. Human female reproductive epithelial cells (SiHa cells apically and basally) were seeded and allowed to polarize over 5-6days. Purified immunoglobulin G (IgG) from *Chlamydia trachomatis* D (CtrD+) seroconverted (Sero+) participants (confirmed by polymerase chain reaction [PCR+]) or naïve human serum was used to opsonize CtrD elementary bodies, which were applied to the apical well under physiological pH of 6.5, then inclusions (IFU) in the basal well were quantified after 48h by immunocytochemistry (A, average IFU per field of view [FOV] is displayed in D). The same purified IgG was used in a direct enzyme-linked immunosorbent assay (ELISA) against CtrD EBs to correlate opsonization with participant (Px) infection status (B). Lastly, CtrD-IgG-positive and negative seminal plasma was used to opsonize CtrD EBs, which were used to infect SiHa cells at pH6.5, then IFU were quantified after 48h by immunocytochemistry (C). N = 3/infection status group, data representative mean and SD of triplicate experiments (A). ELISA data in (B) was assessed for correlation using non-linear regression (exponential growth) and the Spearman correlation test.  $N = 20/CtrD + IgG$  group,  $N = 4/CtrD-IgG$  group (C). Graphs and statistical analysis (unpaired *t* test) was generated in GraphPad Prism (v9), \**P*<.05 (D).

prior to challenge as previously described.[34](#page-13-14) *C.muridarum* (500 IFUs per 20µL) was incubated with 5 or 50µgmL<sup>-1</sup> of infected male IgG (EB IgG) or naïve IgG for 1h on ice prior to infection. Mice were intravaginally infected with 500 IFUs Cmu+IgG under anaesthesia with ketamine (Parnell Laboratory, Alexandria, Australia; 100mgkg−1)/ xylazine (Bayer, Leverkusen, Germany;  $10 \text{ mgkg}^{-1}$ ). In vivo depletion of  $CD8\beta^+$  T cells (Clone: 53-5-8, IgG1, 250μg intraperitoneal, 50μg intravaginally; BioXCell, West Lebanon, NH, USA) or IgG1 isotype control (anti-HRP; BioXCell) was performed the day prior to challenge. Depletion efficiency was assessed previously and the same method was used in this study.<sup>[34](#page-13-14)</sup>

#### **2.7** | **Bone marrow RNA transcription**

Murine bone marrow macrophages or dendritic cells were infected with IgG-opsonized *C.muridarum* (αEB-IgG  $100\mu$ g mL<sup>-1</sup>), or *C. muridarum* + naïve IgG (100 μg mL<sup>-1</sup>) and incubated at 37°C 5%  $CO<sub>2</sub>$  for 2, 4, 6 or 24h. RNA was extracted using Trizol (ThermoFisher) and 10μg of glycogen carrier protein (Cat # AM9510, Applied Biosystems, Foster City, CA, USA) according to the manufacturer's instructions. Complementary DNA was synthesized using High Capacity Reverse Transcriptase Kit (Applied Biosystems) (Cat. # 4368814) as per the manufacturer's instructions. Each reaction contained 10ng of cDNA, 1μM of forward/reverse primers (Sigma Aldrich), 200μM dNTPs, 1.5 mM MgCl<sub>2</sub>,  $1 \times$  buffer, 0.15 $\times$  SYBR green and 5U of Platinum Taq polymerase (ThermoFisher) made up to a final volume of 20μL using sterile nuclease-free water. Reverse transcription PCR was performed using the Corbet Rotorgene Q (Qiagen). Primers for mouse CXCL1, CXCL2, CXCL5, TNF, IL1β and IFNγ mRNA were used as previously described. Mouse Dendritic and Antigen Presenting Cell RT<sup>2</sup> Profiler PCR Array (PAMM-406Z) (Qiagen) was performed as per the manufacturer's instructions on an ABI 7900 HT plate PCR (Applied Biosystems).

## **2.8** | *Chlamydia***-specific proliferation and cytokine production**

Lymphocytes were stained with carboxyfluorescein succinimidyl ester (CFSE) (Sigma Aldrich; 5 μM) for 5min at room temperature. Splenocytes were cultured in RPMI 10% FCS, 100 μg mL<sup>-1</sup> streptomycin sulfate, 50 μg mL<sup>-1</sup> gentamycin, 1× Glutamax and 50 μM b-mercaptoethanol. Labelled splenocytes were seeded into U-bottom 96 well plates  $(5 \times 10^4 \text{ cells/well})$  and stimulated with media containing live (MOI 1) or UV-inactivated  $(10 \mu g m L^{-1})$ *C. muridarum* for 7[2](#page-5-0)h at 37 $\degree$ C with 5% CO<sub>2</sub> (Figure 2) or cultured in media without stimulation (Figure [3\)](#page-6-0). For cytokine production, non-CSFE-labelled cells incubated for 12h in medium containing brefeldin A (Sigma Aldrich;  $10 \mu$ g mL<sup>-1</sup>) prior to intracellular cytokine staining. Cells were washed with 2% (v/v) FCS/PBS before blocking with  $\alpha$ CD16/CD32 IgG (Clone: 24G2) for 15 min at 4°C. Cells were stained with αCD3 IgG-APC Cy7 (Clone 145- 2C11, Cat # 423112, Biolegend, San Diego, CA, USA), αCD4 IgG-V450 (Clone: RM4.5, Biolegend) and αCD8α IgG-PE Cy7 (Clone: 53.6-7, Cat # 25-0081, eBioscience, San Diego, CA, USA) in a volume of  $50 \mu L$  for 15 min at 4°C. Cells were washed with 2% FCS/PBS before fixing with 4% (w/v) paraformaldehyde in PBS for 10min at 4°C. Fixed cells were then permeabilized with Perm/ Wash (Cat # 554723, BD Bioscience, Franklin Lakes, NJ, USA) for 15 min at 4°C. Permeabilized cells were stained with αIFN-γ IgG- APC (Clone: SMG1.2, Cat No. 554413, BD Bioscience), αIL-10 IgG-FITC (Clone: FES5/16E3) and αIL-17a IgG-PE (Clone: TC11-18H10, Cat # 559502, BD Bioscience) diluted in Perm/Wash buffer for 40 min at 4°C. Stained cells were analysed on a FACSAria III (BD Bioscience) using Flowjo version 10.2 software (Tree Star Inc, Ashland, OR, USA). Gating strategy is shown in Figure [S1.](#page-14-2)

#### **2.9** | **Immunohistochemistry**

Paraffin-embedded tissues were sectioned and stained as previously described but with some modifications. $34$ Primary antibody rabbit anti-mouse FcRn-CT ( $5 \mu g \text{mL}^{-1}$ ), and secondary goat anti-rabbit IgG-HRP (1:1000) (Southern Biotechnology). For cryosectioned samples, tissues were snap frozen in Tissue-Tek Optimum Cutting Temperature (OCT) Compound (ProSciTech, Kirwan Australia), and sectioned  $(5 \mu m)$  using a CM3050 S Research Cryostat (Leica Biosystems). Slides were fixed in ice-cold acetone for 10min at 4°C, air-dried for 10min at room temperature and blocked with 5% (v/v) FCS/PBS for 1h at room temperature. Slides were stained with sheep anti-*C. muridarum* MOMP sera (made in-house)<sup>[55](#page-14-3)</sup> for

**ARMITAGE ET AL. 5 of 15**<br>**armitage et al. 5 of 15**<br>**decision in the contract of the contr** 

1h at room temperature. Slides were washed three times with PBS for 5min, and stained with donkey anti-sheep IgG-AlexaFluor 488 (Thermo Fisher), Phallodan-AF594 (Thermo Fisher) and DAPI (Thermo Fisher) for 1h at room temperature. Slides were washed three times with PBS, mounted with Prolong Gold (Thermo Fisher) and analysed with a Leica TCS SP5 confocal microscope (Leica Biosystems).

## **2.10** | **Gross oviduct pathology**

The oviduct diameter was measured on day 35 postinfection to assess the incidence and severity of gross pathology. The severity was determined by increase in size from healthy oviducts (2mm), and incidence of hydrosalpinx was the total number of occluded oviducts (unilateral and bilateral).

## **2.11** | **Power calculations and statistical analysis**

Sample sizes were determined a priori using a onetailed, proportions: inequality, two independent groups Fischer's exact test in G\*Power 3.1.7 software (Institute of Experimental Psychology, Dusseldorf, Germany). Significance is represented using the symbol \*, with \**P*>.05, \*\**P*>.01 and \*\*\**P*>.001. Significance between vaginal shedding was determined using Student *t* tests. The significance of the severity and incidence of hydrosalpinx was determined using Student t test and chi-squared tests, respectively, performed using GraphPad Prism version 7 (GraphPad, La Jolla, CA, USA). The total IFU/ swab (the chlamydial infectious burden) was quantified, and the difference between groups analysed, as area under curve, using GraphPad Prism version 7. As area under curve assesses the bacterial burden, only infected groups are displayed, as the non-infected control has a zero datapoint.

## **3** | **RESULTS**

## **3.1** | **IgG opsonization of** *Chlamydia* **enhances transcytosis across epithelia**

Previous studies have demonstrated a role for IgGmediated enhanced phagocytosis and transcytosis of opsonized antigen and pathogens across mammalian mucosal epithelia $12,13,30-33$ ; hence, we sought to determine if this phenomenon was applicable in the context of chlamydial infections. Purified human IgG was

**6 of 15 WILEY-IMMÜNOLOOV** 



<span id="page-5-0"></span>**FIGURE 2** Vaginal inoculation with optimized *Chlamydia* enhances hydrosalpinx and T cell activation. Female BALB/c mice were infected with 5 (A–C) or 50 (D–E)μgmL−1 of anti-*C.muridarum* (Cmu) elementary body immunoglobulin G (αEB-IgG)-opsonized or non-opsonized *C.muridarum* (Weiss), or plasmid-cured (CM3.1) *C.muridarum* (F–I) for 35days and vaginal shedding (and total burden displayed as area under curve) and hydrosalpinx measured (n=10 mice [20 oviducts]/group). (J) Pooled caudal and lumbar lymph nodes (five mice/group) were taken and stimulated in vitro with ultraviolet (UV)-inactivated Cmu or live Cmu (MOI=1) for 12h and CD4<sup>+</sup> T cell intracellular cytokine production was determined by flow cytometry. (K) Splenocytes from infected mice were labelled with CSFE and stimulated in vitro with UV Cmu or live Cmu for 3 days.  $CD4^+$  and  $CD8^+$  T cell proliferation was determined by flow cytometry. N=10 mice/group, 20 datapoints shown for oviduct measurements as two oviducts per mouse, from one experiment. Graphs and statistical analysis generated in GraphPad Prism (v7), data representative of mean and SD of one experiment. Hydrosalpinx severity (oviduct diameter) was compared between groups with unpaired *t* tests and hydrosalpinx incidence (presence-absence) data were analysed with chi-square, chlamydial shedding data analysed with unpaired *t* tests, \**P*<.05.

used to opsonize *C. trachomatis* EBs, which was applied to polarized pH 6.5 endometrial/cervical epithelial cells (SiHa) using a previously established Transwell cell culture model (Figure [1A](#page-3-0)). *C. trachomatis* serovar D-specific IgG derived from actively infected (PCRpositive) and chlamydial-positive seroconverted donors was found to enhance translocation of EBs across the polarized epithelia to the basolaterally seeded cells (SiHa), whereas donors who were PCR negative and had no *C. trachomatis* D-specific IgG had minimal translocation of *C. trachomatis* D (Figure [1B\)](#page-3-0). As there was a trend towards current infection (PCR) and *C. trachomatis-*specific IgG seroconversion (validated by ICC), direct ELISAs of purified IgG against *C. trachomatis* D EBs were performed, and statistical analysis of translocation revealed a significant correlation



<span id="page-6-0"></span>**FIGURE 3** Opsonization of *Chlamydia* facilitates translocation and lymph node migration. A, UV-inactivated *C.muridarum* (Cmu) was immobilized on ELISA plates and male anti-*C.muridarum* elementary body immunoglobulin G (αEB-IgG) or naïve IgG added. EBs and IgG were detected with sheep anti-major outer membrane protein (MOMP) IgG and visualized with anti-sheep IgG-AF488 and anti-mouse IgG-AF555. B, Isotypes of αEB-IgG were determined by direct ELISA with ultraviolet (UV)-inactivated *C.muridarum* and anti-mouse IgG1- 3-HRP. C, IHC of uninfected mouse cervicovagina and uterine horn tissues was performed to detect FcRn infection. D, Cervicovaginal and E uterine horn tissues of mice infected with *C.muridarum* for 24h were frozen, cryosectioned and IHC was performed with anti-MOMP, counterstained with phalloidin for cytoskeleton and DAPI for nucleus. F, 24h post-infection, lymph nodes were collected, homogenized, fixed and stained with DAPI and anti-inclusion membrane protein A (IncA) IgG and detected with anti-mouse IgG-AF555. G, CD4<sup>+</sup> and  $CD8<sup>+</sup>$  T cell proliferation was determined by flow cytometry without in vitro stimulation. White arrows identify inclusion formation. Images are representative of 10 fields of view per mouse. Scale bars=white (10μm), black (20μm). Fluorescent images captured with SP5 confocal microscope (Leica Biosystems); DAB images captured with using light microscopy. Flow cytometry performed using Aria III (BD Bioscience). Graphs and statistical analysis (unpaired *t* test) generated with GraphPad Prism (v7), data mean and SD. N=3 (A–F) or five (G, pooled nodes) mice/group, from one experiment.

between *C. trachomatis* serovar D EB-specific IgG titre and translocation across epithelia into the basolateral chamber (Figure [1C\)](#page-3-0). Because chlamydial infection of males also induces *Chlamydia*-specific IgG in the male reproductive tract, which could potentially enhance infection in females, seminal plasma-opsonized EBs were applied to the apical surface (SiHa) and allowed to infect. Seminal plasma from *C. trachomatis*-IgG+ donors

significantly (*P*<.05) enhanced infection of basolateral cells (SiHa), compared to *C. trachomatis*-IgG donors (Figure [1D](#page-3-0)). As FcRn is important for IgG transcytosis and translocation of IgG-opsonized antigen in mucosal tissues<sup>12,13,30–33</sup> and has a pivotal role in IgG transcytosis in the mammalian female reproductive tract,<sup>[9](#page-13-1)</sup> we sought to further investigate the role in infection and pathology in a FcRn<sup> $-/-$ </sup> mouse model.

#### **3.2** | **Opsonization of** *Chlamydia* **with male immune IgG enhances female pathology**

Male infection with *C. muridarum* leads to a chronic nonresolving infection in the male reproductive tract, with a chronic viable infection detectable in the prostatic fluid, prostate, penis and testes for at least 10 weeks,<sup>[34](#page-13-14)</sup> and up to 6 months in the testes. $35$  Male infection leads to production of systemic anti-chlamydial EB IgG antibodies detectable in the sera within  $4$  weeks.<sup>36</sup> Male to female sexual transmission of *Chlamydia* in mice is not possible, as female infections require hormone synchronization with progesterone making the females unresponsive to breeding.[34,37,38](#page-13-14) Thus, to simulate sexual transmission of *Chlamydia* from chronically infected males (>10 weeks) which have large concentrations of  $\alpha$ EB-IgG, or acutely infected (<2 weeks) (naïve IgG) prior to seroconversion, chlamydial EBs were incubated with IgG, and then female mice were intravaginally infected with 500 IFUs as this has previously been shown to be a biologically relevant dose.<sup>34</sup> To control for the range of total IgG in male ejaculate, EBs were incubated at the low  $(5 \mu g m L^{-1})$ and high concentrations  $(50 \mu g \text{mL}^{-1})$  prior to infection. Infection of female mice with IgG-opsonized EBs did not significantly alter the kinetics of the infection, nor did it significantly change total chlamydial burden at either the low or high IgG concentrations (Figure [2A,B](#page-5-0)), indicating poor in vivo neutralization by  $\alpha$ EB-IgG. When female mice were infected with less pathogenic and virulent plasmid-cured EBs, αEB-IgG also failed to alter the chlamydial infection kinetics or pathology (Figure [2C\)](#page-5-0). After 6 weeks of infection, oviduct (fallopian tube) occlusion severity and frequency of occurrence (incidence) was recorded (Figure [2D–I](#page-5-0)). Female mice that had been infected with IgG-opsonized EBs had no significant change in the severity of blockage, but interestingly had significantly more incidence of hydrosalpinx, indicating infertility, at both the low and high IgG concentrations (Figure [2E,G](#page-5-0)). Infection of females with opsonized less virulent, plasmid-cured EBs did not spontaneously induce the development of hydrosalpinx (Figure [2I](#page-5-0)) as expected.<sup>[39](#page-13-13)</sup> Caudal and lumbar LN cells collected from mice infected with IgGopsonized Cmu contained significantly more IFNgsecreting CD4<sup>+</sup> cells, when stimulated in vitro with live or UV-inactivated Cmu, compared to cells collected from non-opsonized Cmu-infected mice (Figure [2J](#page-5-0)). IL-17a and IL-10-secreting  $CD4^+$  cell numbers were not significantly different between the groups (Figure [2J](#page-5-0)). Splenocytes from animals infected with IgG-opsonized Cmu contained greater numbers of proliferating CD4 and CD8 cells, following in vitro stimulation with Cmu (Figure [2K\)](#page-5-0). Taken together, these results indicate that opsonization of *Chlamydia* with immune IgG prior to infection does not affect the kinetics or resolution of infection, but significantly enhances the incidence of the immunopathological sequelae and T cell responses to infection.

#### **3.3** | **Translocation of IgG immune complexes and immune activation**

Chlamydial infection of male mice induces a chronic upper reproductive tract infection lasting 6 months,  $35$ which facilitates a robust and consistent adaptive immune response. Opsonization of EBs with male IgG did not significantly alter the kinetics of infection (Figure [2A–D](#page-5-0)) but enhanced the incidence of hydrosalpinx (Figure [2E,F](#page-5-0)), we therefore sought to determine the mechanism of action. Purified male αEB-IgG was found to co-localize with immobilized chlamydial EBs indicating purification did not affect the ability of IgG to bind infectious *Chlamydia* (Figure [3A\)](#page-6-0). Conversely, naïve mouse IgG did not bind chlamydial EBs, indicating antigen-specific binding, and not Fc/Fab-mediated binding observed in other bacteria. Anti-chlamydial EB ( $\alpha$ EB)-IgG (specifically IgG<sub>2a</sub> and IgG<sub>2b</sub>) were detected in the sera of male mice infected for 10 weeks, indicative of a strong  $IgG_{2a}$ :IgG<sub>1</sub> Th1 bias during male infection consistent with previous studies (Figure [3B\)](#page-6-0).<sup>[12,36](#page-13-12)</sup> In female mice hormonally synchronized with DepoProvera, FcRn expression was detectable in the vagina and uterine horns prior to infection (brown DAB staining, Figure  $3C$ ) consistent with previous studies.<sup>[11](#page-13-2)</sup>

We have previously shown that opsonization of *Chlamydia* with IgG from MOMP-immunized animals can also enhance pathology by translocation across epithelia, dependent on FcRn expression. $^{12}$  To determine where this was happening in vivo, female mice were infected for 24 h allowing EB uptake and inclusion development within one cycle of infection. IHC of females infected for 24 h showed chlamydial infection of stratified squamous epithelia of the cervicovagina in both the EB-IgG-opsonized and control IgG *Chlamydia* groups indicating luminal infection of cells at the mucosal barrier (Figure [3D](#page-6-0)). Interestingly, in the mouse, uterus replicating *Chlamydia* were detected below the simple columnar epithelial layer in the laminar propria of IgGopsonized EBs infected mice, but not in non-opsonizedinfected mice suggesting translocation of IgG immune complexes occurred in the uterus (Figure [3E](#page-6-0)).

In addition to stromal fibroblasts, leukocytes (particularly antigen-presenting cells [APCs]) are present in the lamina propria which phagocytose antigens, migrate

along afferent lymph vessels to draining lymph nodes and activate the adaptive immune response. To determine if replicating *Chlamydia* had been trafficked to the draining lymph node, caudal and lumbar lymph nodes were collected 1day post-infection. Lymphatic cells were stained using an anti-inclusion membrane antibody which detects replicating *Chlamydia*. In mice infected with IgGopsonized EBs, there were significantly more  $IncA<sup>+</sup>$ (actively replicating) cells in the draining lymph nodes (Figure [3F](#page-6-0)) indicating viable and replicating *Chlamydia* had been trafficked to the lymphatics inside APCs. Three days after infection, lymph node cells were collected, labelled with CFSE and cultured in vitro for three additional days. CSFE-proliferation of  $CD4^+$  and  $CD8^+$  T cells (Figure [3G](#page-6-0)) was determined by flow cytometry.  $CD4^+$  and  $CD8<sup>+</sup>$  T cells isolated from the draining lymph nodes of mice infected with IgG-opsonized *Chlamydia* proliferated more than 10-fold more than cells from mice infected with non-opsonized infections, suggesting APCs in the lymph node were rapidly presenting antigen and stimulating rapid T cell responses. Taken together, these data suggest that EBs opsonized with IgG from infected males can rapidly translocate infectious EBs across simple epithelia, infecting and replicating inside APCs which rapidly traffic to draining lymph nodes and enhance  $CD4^+$  and  $CD8^+$  T cell proliferation.

#### **3.4** | **Opsonization of** *Chlamydia* **alters APC activation**

*Chlamydia* spp. can infect APCs altering their phenotype.<sup>11,20</sup> To investigate the role opsonizing chlamydial EBs in males αEB-IgG has on female APCs, bone marrow macrophages  $(BMM_{O})$  and dendritic cells (BMDC) were generated and infected with IgG-opsonized or non-opsonized *C.muridarum* (Figure [4A\)](#page-9-0). Phagocytosis of *Chlamydia* did not result in uptake and killing of chlamydial EBs, and flow cytometry for inclusion membrane production demonstrated replication in both opsonized and non-opsonized EBs, with enhanced production of IncA (active replication marker) in BMDCs infected with opsonized EBs (Figure [4B](#page-9-0)). Infection of BMDCs also led to increased in vitro stimulation of CD4<sup>+</sup> and CD8<sup>+</sup> T cells from splenocytes collected from previously infected female mice (Figure [4C](#page-9-0)).

To determine the kinetics of mRNA translation during infection, BMDCs were infected with non-opsonized or opsonized *C.muridarum* and samples taken over a 24h period (Figure [4D](#page-9-0)). Infection of BMDCs with EBs opsonized with male IgG enhanced expression of chemokines CXCL1, CXCL2, CXCL5 and pro-inflammatory cytokines TNF, IL1β and IFNγ compared to uninfected or non-opsonized controls.

**ARMITAGE ET AL.** 9 of 15

To determine the extent and change in APC differentiation,  $BMM_{\alpha}$  and  $BMDCs$  were infected with opsonized or non-opsonized EBs for 24h and mRNA analysed with an Antigen Presentation RT Array (Figure [4E\)](#page-9-0). Infection of  $BMM_{\odot}$  with IgG-opsonized EBs upregulated mRNA transcription of chemokines and cytokines *Ccl2/MCP-1* (highest, 7245-fold), *Ccl12/MCP-5*, *Ccl20/MIP-3A* and *Il10*; antigen presentation *Cd1d2*, *Cd8α* (highest, 6015-fold), *Cd36*, *Cd40*, *Cd40lg/Tnfsf5*, *Cd86*, *Cd209a/DC-SIGN* and *Icam*; and signal transduction *Cdkn1a*, *Csf1r*, *Fas*, *Flt3*, *Lyn* (highest, 5515-fold), *Mif* and *Rela*. Conversely, infection of BMM<sub>Ø</sub> with IgG-opsonized *Chlamydia* upregulated mRNA transcription of chemokines and cytokines *Ccl11*, *Ccl2/ MCP-1* (highest, 5537-fold), *Ccl7/MCP-3* and *Ifnγ*; antigen presentation and chemotaxis *Cd8α*, *Cd28*, *Cd33*, *Cd40lg/ Tnfsf5*, *Cd86* (highest, 4842-fold), *Cdc42*, *Clec4b2*, *Csf2/GM-CSF*, *Cxcr4*, *H2-DMa/MHC-2*, *Icam1* and *Rac1*; and signal transduction *Lyn* (highest, 118-fold), *Nfkβ1* and *Rela*.

Dendritic cells are considered pivotal in antigen presentation and induction of adaptive immunity and behaved considerably different to  $BMM_{\alpha}$  following uptake of IgG-opsonized or non-opsonized *Chlamydia*. Infection of BMDCs with non-opsonized Cmu, assessed via gene array, upregulated mRNA for chemokines and cytokines *Ccl2/MCP-1*, *Ccl11/Eotaxin* (highest, 47 673-fold), *Ccr1*, *Il6*, *Il12α*, *Il12β*, *Tnf* and *Csf2/GM-CSF*; antigen processing and chemotaxis *Cd2*, *Cd4*, *Cd28*, *Cd40*, *Cdc42* (highest, 6880-fold), *Cxcr1*, *Cxcr4*, *Icam1* and *Fcgr1/CD64*; and signal transduction *Cebpa* (highest, 28, 565-fold), *Erbb2*, *Nfkβ1*, *Ptprc*, *Rag1* and *Relb*. Conversely, infection with IgG-opsonized *Chlamydia* led to the upregulation of mRNA for chemokines and cytokines *Ccl2*, *Ccl5/RANTES*, *Ccl8/MCP-2*, *Il6* (highest, 5928-fold), *Csf2/GM-CSF* and *Ifnγ*; antigen processing and chemotaxis *Cd2*, *Cd40*, *H2- DMa/MHC-2*, *Icam1* and *Icam2* (highest, 744-fold); and signal transduction *Flt3I* (37-fold). Taken together, opsonization of *Chlamydia* with male αEB-IgG prior to infection significantly alters the antigen processing and activation of both macrophages and dendritic cells, resulting in enhanced inflammatory and migratory signalling when APCs phagocytose male IgG-opsonized *Chlamydia*.

#### **3.5** | **FcRn trafficking of immune complexes mediates enhancement of pathology dependent on CD8<sup>+</sup> T cells**

Opsonization of *Chlamydia* prior to infection was found to enhance pathology in vivo (Figure [2\)](#page-5-0); thus, we sought to address what was driving the enhancement of pathology using knockout mice and depletion studies. It has previously been demonstrated that cross presentation of IgG:IC by dendritic cells can enhance  $CD8<sup>+</sup>$  T production,  $31$  and



<span id="page-9-0"></span>**FIGURE 4** Opsonization of *Chlamydia* alters APC activation and antigen presentation. A, Bone marrow-derived macrophages (BMMØ) and dendritic cells (BMDC) were infected with *C.muridarum* (Cmu, MOI1) for 24h, stained for major outer membrane protein (MOMP) expression and imaged with a fluorescent microscope. B, BMDCs were infected for 24h with opsonized (100µgmL<sup>-1</sup>) or nonopsonized *C.muridarum*, fixed and stained with anti-inclusion membrane protein A (IncA) mAb-PE and analysed by flow cytometry (Aria III, BD Bioscience). C, BMDCs were infected (+/− IgG opsonization) for 24h, and then incubated with CSFE-labelled splenocytes from *C.muridarum*-infected female mice (day 35 post-infection) for 3days analysed for CD3<sup>+</sup> CD4<sup>+</sup> and CD8<sup>+</sup> expression by flow cytometry. D, BMDCs were seeded into 24-well plates and were infected with *C.muridarum* (MOI=1) (+/− opsonization) and mRNA collected over 24h. qRT-PCR was performed on a Rotorgene Thermocycler. E, Bone marrow-derived macrophages ( $BMM<sub>Q</sub>$ ) and bone marrow-derived dendritic cells (BMDCs) were seeded into a 6-well plate and infected with *C.muridarum* (MOI=1) (+/− opsonization) for 24h. RT-PCR was performed using a Dendritic and Antigen Presentation RT2 Array (Qiagen) analysed on 7900HT FAST ABI. White arrows indicate chlamydial inclusion. Scale bar = 10  $\mu$ m. Graphs generated with GraphPad Prism (v7). N = 5 mice/group, pooled, from one experiment.

CD8<sup>+</sup> T cells generated in response to vaginal chlamydial infection are also immunopathogenic as evidenced by the lack of hydrosalpinx in OT-I mice.<sup>40</sup> To determine if FcRn was mediating enhancement of immunopathology, we infected WT and  $FcRn^{-/-}$  mice with IgG-opsonized or nonopsonized *Chlamydia*. Unlike previous infections of WT mice (Figure [2](#page-5-0)), opsonization of *Chlamydia* with IgG prior to infection led to significant reductions in the kinetics, peak, duration and total burden of *Chlamydia* in FcRn−/− mice alone (Figure [5A,B\)](#page-10-0). However, WT and  $FcRn^{-/-}$  did not have any significant differences when infected with non-opsonized *Chlamydia* demonstrating the reduction

in burden in FcRn−/− mice was dependent on opsonization. To determine the role of FcRn and CD8<sup>+</sup> T cells, the mice were depleted (or mock depleted) of  $CD8<sup>+</sup>$  T cells 24h prior to infection and hydrosalpinx measured after 6 weeks. In WT mice that had been depleted of  $CD8<sup>+</sup>$  T cells or mock depleted and then had been infected with opsonized or non-opsonized *Chlamydia*, there was no significant reduction in severity or incidence of hydrosalpinx suggesting a limited role for  $CD8<sup>+</sup>$  T cells during the early stages of infection (Figure [5C,D](#page-10-0)). Interestingly, in FcRn−/− mice infected with opsonized *Chlamydia*, there was a significant reduction in incidence of pathology if



<span id="page-10-0"></span>**FIGURE 5** FcRn-mediated translocation enhances CD8 immunopathology. (A, B), Female wild-type (WT) and FcRn knockout (−/−) mice were infected with *Chlamydia muridarum* (Cmu, +/− opsonization with 50μgmL−1 IgG) for 35days and vaginal shedding determined by culture (N=5-10, in one experiment), with total burden displayed as area under curve. (C, D), Female WT or FcRn−/− mice were depleted or mock depleted of CD8β<sup>+</sup> T cells (Clone: 53-5-8, IgG1, 250μg intraperitoneal injection, 50μg intravaginally; BioXCell, West Lebanon, NH, USA) 1 day prior to being infected with opsonized (male anti-*C. muridarum* IgG [αEB-IgG] 50μgmL<sup>-1</sup>) or non-opsonized (naïve IgG 50μgmL−1) *C.muridarum*. Hydrosalpinx occurrence and severity (diameter, mm) was measured 35days post-infection. (N=9-10 mice/ group from one experiment). Graphs (mean and SD) and statistical analysis (two-way-ANOVA) was completed in GraphPad Prism (v7), \**P*<.05, \*\*\**P*<.001.

 $CD8<sup>+</sup>$  T cells were also depleted prior to infection (94%-22%). This protection was also significantly more than in FcRn−/− mice infected with non-opsonized *Chlamydia* and depleted of  $CD8<sup>+</sup>$  T cells (50%-22%) suggesting EB-IgG opsonization prior to infection improved the protection afforded from depleting cytotoxic T cells. In WT and  $FcRn^{-/-}$  mice depleted of CD8<sup>+</sup> T cells and infected with opsonized *Chlamydia*, there was a significant reduction in pathology in the absence of FcRn suggesting in the absence of IgG:IC transcytosis, CD8 depletion early during female infection is more protective against hydrosalpinx.

## **4** | **DISCUSSION**

Urogenital chlamydial infections affect both males and females, and the deleterious immunopathology adversely afflicting females is studied widely; yet, chlamydial infections are asymptomatic in 70%-90% of females<sup>41</sup> leading to under-diagnosis, continued dissemination and chronic inflammation that can cause scarring and infertility. Similarly, males are asymptomatic in 30%-50% of *C.trachomatis* urogenital infections $41$  and while the immunopathology can lead to chronic infections of the prostate and testes, male infections and the implications on infertility are poorly understood and understudied. As chronically infected male mice can harbour an active infection  $>10$  weeks<sup>34</sup> and is culturable for at least 6 months in the

testes, $35$  and seroconvert with a Th1-bias within 1 month of infection, we sought to determine if IgG antibodies generated in response to a chlamydial infection in males could influence the outcome of infection and immunopathology in females, mimicking sexual transmission. While secretory IgA may also play a role in steric blocking of *Chlamydia* and the host response to infection,<sup>42,43</sup> FcRn does not bind IgA and there is generally low titre IgA within seminal fluid (relevant for mimicry of sexual transmission) compared to  $IgG<sub>1</sub><sup>44</sup>$  leading this study to focus on IgG.

Monoclonal and polyclonal IgG antibodies generated following immunization with MOMP have been demonstrated to enhance infectivity of *C.trachomatis* and *C.muridarum* in vitro via FcγR-mediated uptake on epithelial cells, $12,28$  including uptake by FcRn.<sup>12</sup> We have also previously demonstrated that MOMP-specific IgG can translocate infectious *Chlamydia* across epithelial barriers infecting underlying cells, dependent on FcRn-mediated translocation under acidic luminal conditions. $^{12}$  This phenomenon has also been reported in HIV infections with FcRn-mediated translocation of IgG-opsonized HIV across polarized endometrial epithelial cells monolayers, also dependent of acidic luminal conditions.<sup>13</sup> The 19 serovars of *C.trachomatis* were originally differentiated based on serotyping of IgG binding to MOMP, and the divergence of the MOMP serovars is derived predominantly from variability of surface-exposed domains of MOMP on **12 of 15 WILEY-IMMÜNOLOGY ARMITAGE ET AL.** 

the surface of EBs. Thus, we sought to determine if the phenomenon of enhanced chlamydial infection observed with MOMP-specific IgG in vitro and in vivo was repeatable using IgG antibodies generated during a natural male infection, and then infecting female mice with opsonized *Chlamydia*.

To determine if translocation of infection could also occur in vivo, naïve female mice were infected with *C.muridarum* opsonized with male IgG, and tissues were taken 1day later. Consistent with human in vitro studies, opsonization of *C.muridarum* failed to prevent infection of female mice, with chlamydial inclusions detected in both the cervicovaginal and endometrial epithelium. Interestingly, and consistent with the in vitro findings, IgG-opsonization of *Chlamydia* facilitated translocation across the uterine epithelia into the lamina propria, but not in the vaginal tissues. Significantly more replicating (IncA<sup>+</sup> staining) *Chlamydia* was detectable in the lymph nodes draining the female reproductive tract, in females infected with opsonized EBs. Furthermore, lymph node homogenates collected from female mice infected with opsonized EBs were also able to rapidly facilitate CD4<sup>+</sup> and CD8<sup>+</sup> T cell proliferation without the requirement for exogenous antigen stimulation. Taken together, these data demonstrate male antibodies generated to natural infection can enhance female infection during transmission, translocating infection across epithelial cells in the upper FRT and enhancing infection and activation of antigenpresenting cells which rapidly migrate into draining lymph nodes, and enhance T cell differentiation.

The dynamics of *C.trachomatis* infection of antigen-presenting cells; specifically, professional antigen-presenting cells, including dendritic cells and macrophages, has been widely studied. $^{20}$  $^{20}$  $^{20}$  The role of IgG-opsonization on antigen presentation on chlamydial infection of antigen-presenting cells is less well elucidated, but mouse macrophages with functional  $Fc\gamma R_I$ (CD64), Fc $\gamma R_{IIB1}$  (CD32) and Fc $\gamma R_{III}$  (CD16) have enhanced antibody-dependent cellular cytotoxicity (ADCC) killing of infected cells and enhance Th1 responses in vitro, compared to FcγR-deficient macrophages and antibody controls.<sup>45</sup> In this study, we observed infection of both macrophages and dendritic cells. Opsonization of EBs with IgG enhanced viable  $(IncA<sup>+</sup>)$  chlamydial infection of dendritic cells, and enhanced in vitro proliferation of CD4<sup>+</sup> CD8<sup>+</sup> T cell proliferation of splenocytes from infected mice. Infection of APCs with opsonized EBs enhanced expression of chemokines CXCL1, 2, 5 and proinflammatory cytokines IL1β and IFNγ and TNF mRNA. Similarly, antigen presentation and maturation of dendritic cell and macrophages infected with opsonized EBs significantly alters the transcriptome of the cells towards a pro-inflammatory phenotype, which phenotypically enhances  $CD4^+$  and  $CD8^+$  T cell proliferation, that is, APC infected with opsonized *Chlamydia* rapid traffic to draining lymph nodes and express pro-inflammatory markers, facilitating chlamydial-specific T cell proliferation.

While opsonization of EBs with male IgG enhanced translocation and antigen presentation in vitro and in vivo, the kinetics of chlamydial shedding from the vagina of naïve mice remained unchanged, regardless of dose of IgG. However, and importantly in case of immunopathology, there was a significant and dose-dependent enhancement of the incidence of oviduct occlusion/hydrosalpinx (infertility) in female mice infected with IgGopsonized *Chlamydia*. This phenomenon was chlamydial plasmid-independent, and was associated with enhanced Th1 (IFNγ production) and doubling the proliferation of  $CD4^+$  and  $CD8^+$  T cells. This demonstrates that male IgG, at doses exceeding the upper limits of IgG concentration in ejaculate, is insufficient to prevent infection of naïve females, and can enhance immunopathology and infertility.

Surprisingly, the enhanced production of  $CD4^+$  and CD8<sup>+</sup> T cells did not accelerate the vaginal clearance or total burden, suggesting that enhancing Th1 responses to whole *Chlamydia* does not necessarily support the clearance of the infection. This is in contrast to other studies finding that  $CD4^+$  T cells are necessary and sufficient to both clear infection, and prevent reinfection.<sup>46</sup> This may suggest that the phenotype of Th1 cells generated plays a more important role than simply the numbers of  $CD4^+$  T cells generated or amount of IFNγ produced. While numerous studies (including our own) have identified an important role for  $CD4^+$  T cells in protection from pathol-ogy, particularly in the context of vaccination,<sup>[34,47](#page-13-14)</sup> the enhancement of *Chlamydia*-specific CD4<sup>+</sup> T cells producing IFNγ in response to infection with opsonized EBs did not result in a reduced incidence of hydrosalpinx. However, oviduct occlusion may have occurred prior to the generation of sufficient numbers of protective *Chlamydia*specific  $CD4^+$  T cells.

Cytotoxic  $CD8<sup>+</sup>$  T cells play a controversial role in chlamydial infections. While it would seem obvious that an obligate intracellular pathogen would be particularly vulnerable to  $CD8<sup>+</sup>$  T cell-mediated killing of infected cells (in the same way that many viral infections are), the chlamydial literature appears to suggest the opposite. Murthy and colleagues demonstrated that  $CD8<sup>+</sup>$  T cells producing TNF in response to infection contribute significantly to hydrosalpinx formation, $48$  and they went on to demonstrate that minimal hydrosalpinx develops in OT-I mice which have a  $CD8<sup>+</sup>$  T cell repertoire limited to ovalbumin peptide  $(Ova_{257-264})$ .<sup>49</sup> Hydrosalpinx in OT-I mice could be reverted to that of WT mice when they received a pool of enriched naïve  $CD8<sup>+</sup>$  T cells from WT mice.<sup>[49](#page-14-9)</sup> This strongly suggests *Chlamydia*-specific CD8<sup>+</sup> T cells generated in response to infection (and not non-specific inflammation or cytotoxicity) contribute significantly to upper FRT pathology, leading this study to focus on  $CD8<sup>+</sup>$ T cells for depletion.

 $CD8<sup>+</sup>$  T cells typically respond to endogenous antigen presented by APCs via MHC-I, but can also respond to exogenous (or phagocytosed) antigen presented by DCs through a process termed 'cross-presentation'. CD8-CD11b<sup>+</sup> DCs bind IgG:IC via FcγR, phagocytosing the ICs, which are acidified allowing intracellular FcRn to bind the IgG:IC and trafficking it to the proteasome for MHC-I-loading.<sup>31</sup> This process facilitates enhanced CD8<sup>+</sup> T cell proliferation and production of pro-inflammatory effector functions including IFN $\gamma$ , TNF and granzyme B production.<sup>31</sup> In this study, the cross-presentation and enhanced expansion of the immunopathogenic *Chlamydia*-specific CD8 T cell pool could be greatly ameliorated in the absence of FcRn, and with prior depletion of the naïve CD8 T cell population.

The delivery of antigen/pathogens opsonized in IgG to APCs has long been known to enhance immunogenicity and killing of pathogens. Mucosal transport of IgG-opsonized Ag across epithelial barriers provides the immune system the opportunity to rapidly respond to primary infection (e.g. when male IgG-Ag is delivered to a naïve partner), or more commonly in recall immunity to secondary infection (self-IgG rapidly delivering IgGbound Ag from the mucosal lumen and expanding memory T cells). This rapid augmentation of immunity allows delivery of Ag to APCs in the lamina propria without the need to disrupt the barrier integrity of the epithelium. FcγR-mediated uptake of most pathogens leads to phagosolysosomal degradation and rapid killing. However, pathogens that are able to escape IgG/FcγR-mediated phagocytosis and phagolysosomal degradation (e.g. *Chlamydia* spp.) can utilize this pathway as a Trojan horse to enhance infection and escape killing. Regardless, FcRnmediated transcytosis of luminal IgG-bound pathogens is likely to be protective and thus beneficial in immunity in most circumstances consistent with the conservation of the *Fcgrt* gene across the class Mammalia. As shown here, *Chlamydia* spp. may be an exception to this rule.

This study supports mucosal delivery of antigen– antibody complexes has been demonstrated to enhance protective immune responses against infectious disease and tumours.<sup>[50](#page-14-10)</sup> Conjugation of the herpes simplex virus 2 (HSV2) glycoprotein D to the Fc fragment of IgG enhanced FcRn-mediated transcytosis of HSV2 antigen to DCs in the lung, and together with the adjuvant CpG provided long-term immunity from lethal challenge in mice. This may be an interesting approach for future studies in mucosal delivery of chlamydial antigens. Additionally, future experiments should utilize whole ejaculate from infected mice for a wholistic and physiologically relevant

**ARMITAGE ET AL. 13 of 15**<br>**12 of 15** 

approach, including immune factors like complement which effect chlamydia viability. $51,52$  This may help elucidate any potential clinical relevance and the mechanism for the 15%-22% reduction in pathology of fertility observed in this study.

#### **ACKNOWLEDGMENTS**

This work was supported by the Australian Government with a National Health and Medical Research Council (NHMRC) grant (ID: 1049571). We thank Professor Peter Timms for his contribution towards acquiring this funding. We also thank Ms Donna West and staff from the Medical Engineering Research Facility (MERF) for breeding, monitoring and housing the mice used in these experiments. We also thank the staff at QFG particularly Ms Zoe Nott for assistance in collecting human seminal plasma samples. We also thank Professor John Aaskov for the L929 cell line (QUT). We also thank Mr Clay Winterford and Dr Nigel Waterhouse at the HisoTechnology Facility— Queensland Institute of Medical Research Berghofer (QIMR-B) for assistance in preparing tissues for immunohistochemistry. Open access publishing facilitated by Queensland University of Technology, as part of the Wiley - Queensland University of Technology agreement via the Council of Australian University Librarians.

#### **DATA AVAILABILITY STATEMENT**

The data that supports the findings of this study are available in the supplementary material of this article.

#### **ORCID**

*EmilyR. Bryan*  $\bullet$  <https://orcid.org/0000-0002-8912-6878>

#### **REFERENCES**

- <span id="page-12-0"></span>1. WHO. Sexually transmitted infections (STIs). *Fact Sheets*. [Website]. 2022. [https://www.who.int/news-room/fact-sheets/](https://www.who.int/news-room/fact-sheets/detail/sexually-transmitted-infections-(stis)) [detail/sexually-transmitted-infections-\(stis\).](https://www.who.int/news-room/fact-sheets/detail/sexually-transmitted-infections-(stis)) Accessed March 31, 2023.
- <span id="page-12-1"></span>2. CDC. *Centres for Disease Control and Prevention. Sexually Transmitted Disease Surveillance*. Department of Health and Human Services; January 2014, 2014.
- <span id="page-12-2"></span>3. US Department of Health and Human Services CfdcapC. Sexually Transmitted Disease Surveillance. 2008.
- <span id="page-12-3"></span>4. Peipert JF. Clinical practice. Genital chlamydial infections. *N Engl J Med*. 2003;349(25):2424-2430.
- <span id="page-12-4"></span>5. Wong WF, Chambers JP, Gupta R, Arulanandam BP. *Chlamydia* and its many ways of escaping the host immune system. *J Pathog*. 2019;2019:8604958.
- <span id="page-12-5"></span>6. Brunham RC, Rey-Ladino J. Immunology of *Chlamydia* infection: implications for a *Chlamydia trachomatis* vaccine. *Nat Rev Immunol*. 2005;5(2):149-161.
- <span id="page-12-6"></span>7. O'Meara C, Andrew D, Beagley K. The mouse model of *Chlamydia* genital tract infection: a review of infection, disease, immunity and vaccine development. *Curr Mol Med*. 2014;14(3):396-421.

**14 of 15 WILEY-HAMITAGE ET AL.** ARMITAGE ET AL.

- <span id="page-13-0"></span>8. Smith PD, MacDonald TT, Blumberg RS, eds. *Principles of Mucosal Immunology*. New York City: Garland Science; 2012 Secretory Immunoglobulins and Their Transport; No. 1.
- <span id="page-13-1"></span>9. Roopenian DC, Akilesh S. FcRn: the neonatal fc receptor comes of age. *Nat Rev Immunol*. 2007;7(9):715-725.
- 10. Pyzik M, Kozicky LK, Gandhi AK, Blumberg RS. The therapeutic age of the neonatal fc receptor. *Nat Rev Immunol*. 2023;23(7):415-432.
- <span id="page-13-2"></span>11. Li Z, Palaniyandi S, Zeng R, Tuo W, Roopenian DC, Zhu X. Transfer of IgG in the female genital tract by MHC class Irelated neonatal fc receptor (FcRn) confers protective immunity to vaginal infection. *Proc Natl Acad Sci U S A*. 2011; 108(11):4388-4393.
- <span id="page-13-12"></span>12. Armitage CW, O'Meara CP, Harvie MCG, Timms P, Blumberg RS, Beagley KW. Divergent outcomes following transcytosis of IgG targeting intracellular and extracellular chlamydial antigens. *Immunol Cell Biol*. 2014;92(5):417-426.
- <span id="page-13-20"></span>13. Gupta S, Gach JS, Becerra JC, et al. The neonatal fc receptor (FcRn) enhances human immunodeficiency virus type 1 (HIV-1) transcytosis across epithelial cells. *PLoS Pathog*. 2013;9(11):e1003776.
- 14. Yoshida M, Claypool SM, Wagner JS, et al. Human neonatal fc receptor mediates transport of IgG into luminal secretions for delivery of antigens to mucosal dendritic cells. *Immunity*. 2004;20(6):769-783.
- 15. Knee RA, Hickey DK, Beagley KW, Jones RC. Transport of IgG across the blood-luminal barrier of the male reproductive tract of the rat and the effect of estradiol administration on reabsorption of fluid and IgG by the epididymal ducts. *Biol Reprod*. 2005;73(4):688-694.
- <span id="page-13-3"></span>16. Levine N, Kelly H. Measurement of pH in the rat epididymis in vivo. *J Reprod Fertil*. 1978;52(2):333-335.
- <span id="page-13-4"></span>17. Fair WR, Cordonnier JJ. The pH of prostatic fluid: a reappraisal and therapeutic implications. *J Urol*. 1978;120(6):695-698.
- <span id="page-13-5"></span>18. Riedewald S, Kreutzmann IM, Heinze T, Saling E. Vaginal and cervical pH in normal pregnancy and pregnancy complicated by preterm labor. *J Perinat Med*. 1990;18(3):181-186.
- <span id="page-13-6"></span>19. Cochrane M, Armitage CW, O'Meara CP, Beagley KW. Towards a *Chlamydia trachomatis* vaccine: how close are we? *Future Microbiol*. 2010;5(12):1833-1856.
- <span id="page-13-21"></span>20. Beagley KW, Huston WM, Hansbro PM, Timms P. Chlamydial infection of immune cells: altered function and implications for disease. *Crit Rev Immunol*. 2009;29(4):275-305.
- <span id="page-13-7"></span>21. Bryan ER, Kollipara A, Trim LK, et al. Hematogenous dissemination of *Chlamydia muridarum* from the urethra in macrophages causes testicular infection and sperm DNA damage. *Biol Reprod*. 2019;101:748-759.
- <span id="page-13-8"></span>22. Fields KA, Hackstadt T. The chlamydial inclusion: escape from the endocytic pathway. *Annu Rev Cell Dev Biol*. 2002;18(1): 221-245.
- <span id="page-13-9"></span>23. Zhong G, Fan T, Liu L. *Chlamydia* inhibits interferon gammainducible major histocompatibility complex class II expression by degradation of upstream stimulatory factor 1. *J Exp Med*. 1999;189(12):1931-1938.
- 24. Zhong G, Liu L, Fan T, Fan P, Ji H. Degradation of transcription factor RFX5 during the inhibition of both constitutive and interferon gamma-inducible major histocompatibility complex class I expression in *Chlamydia*-infected cells. *J Exp Med*. 2000;191(9):1525-1534.
- <span id="page-13-10"></span>25. Carabeo RA, Grieshaber SS, Fischer E, Hackstadt T. *Chlamydia trachomatis* induces remodeling of the actin cytoskeleton during attachment and entry into HeLa cells. *Infect Immun*. 2002;70(7):3793-3803.
- <span id="page-13-11"></span>26. Joller N, Weber SS, Muller AJ, et al. Antibodies protect against intracellular bacteria by fc receptor-mediated lysosomal targeting. *Proc Natl Acad Sci U S A*. 2010;107(47):20441-20446.
- 27. Scidmore MA, Rockey DD, Fischer ER, Heinzen RA, Hackstadt T. Vesicular interactions of the *Chlamydia trachomatis* inclusion are determined by chlamydial early protein synthesis rather than route of entry. *Infect Immun*. 1996;64(12):5366-5372.
- 28. Su H, Spangrude GJ, Caldwell HD. Expression of fc gamma RIII on HeLa 229 cells: possible effect on in vitro neutralization of *Chlamydia trachomatis*. *Infect Immun*. 1991;59(10):3811-3814.
- 29. Cunningham KA, Carey AJ, Hafner L, Timms P, Beagley KW. *Chlamydia muridarum* major outer membrane protein-specific antibodies inhibit in vitro infection but enhance pathology in vivo. *Am J Reprod Immunol*. 2010;4:4.
- 30. Baker K, Qiao SW, Kuo T, et al. Immune and non-immune functions of the (not so) neonatal fc receptor, FcRn. *Semin Immunopathol*. 2009;31(2):223-236.
- <span id="page-13-15"></span>31. Baker K, Qiao SW, Kuo TT, et al. Neonatal fc receptor for IgG (FcRn) regulates cross-presentation of IgG immune complexes by CD8−CD11b<sup>+</sup> dendritic cells. *Proc Natl Acad Sci U S A*. 2011;108(24):9927-9932.
- 32. Ohsaki A, Venturelli N, Buccigrosso TM, et al. Maternal IgG immune complexes induce food allergen-specific tolerance in offspring. *J Exp Med*. 2018;215(1):91-113.
- 33. Qiao S-W, Kobayashi K, Johansen F-E, et al. Dependence of antibody-mediated presentation of antigen on FcRn. *Proc Natl Acad Sci U S A*. 2008;105(27):9337-9342.
- <span id="page-13-14"></span>34. O'Meara CP, Armitage CW, Kollipara A, et al. Induction of partial immunity in both males and females is sufficient to protect females against sexual transmission of *Chlamydia*. *Mucosal Immunol*. 2016;9(4):1076-1088.
- <span id="page-13-16"></span>35. Bryan ER, Redgrove KA, Mooney AR, et al. Chronic testicular *Chlamydia muridarum* infection impairs mouse fertility and offspring development†. *Biol Reprod*. 2020;102:888-901.
- <span id="page-13-17"></span>36. Pal S, Peterson EM, de la Maza LM. New murine model for the study of *Chlamydia trachomatis* genitourinary tract infections in males. *Infect Immun*. 2004;72(7):4210-4216.
- 37. Tuffrey M, Taylor-Robinson D. Progesterone as a key factor in the development of a mouse model for genital-tract infection with *Chlamydia trachomatis*. *FEMS Microbiol Lett*. 1981;12(2):111-115.
- 38. Green EL (Ed.) *Biology of the laboratory mouse*. New York: Dover Publications Inc; 1975.
- <span id="page-13-13"></span>39. O'Connell CM, Ingalls RR, Andrews CW Jr, Scurlock AM, Darville T. Plasmid-deficient *Chlamydia muridarum* fail to induce immune pathology and protect against oviduct disease. *J Immunol*. 2007;179(6):4027-4034.
- <span id="page-13-18"></span>Manam S, Nicholson BJ, Murthy AK. OT-1 mice display minimal upper genital tract pathology following primary intravaginal *Chlamydia muridarum* infection. *Pathog Dis*. 2013;67(3):221-224.
- <span id="page-13-19"></span>41. Stamm WE. *Chlamydia trachomatis* infections: progress and problems. *J Infect Dis*. 1999;179(Suppl 2):S380-S383.
- <span id="page-14-4"></span>42. Cunningham KA, Carey AJ, Finnie JM, et al. Polyimmunoglobulin receptor-mediated transport of IgA into the male genital tract is important for clearance of *Chlamydia muridarum* infection. *Am J Reprod Immunol*. 2008;60(5):405-414.
- 43. Armitage CW, O'Meara CP, Harvie MC, Timms P, Wijburg OL, Beagley KW. Evaluation of intra- and extra-epithelial secretory IgA in Chlamydial infections. *Immunology*. 2014;143(4):520-530.
- <span id="page-14-5"></span>44. Walker BA, Wardell CP, Chiecchio L, et al. Aberrant global methylation patterns affect the molecular pathogenesis and prognosis of multiple myeloma. *Blood*. 2011;117(2):553-562.
- <span id="page-14-6"></span>45. Moore T, Ananaba GA, Bolier J, et al. Fc receptor regulation of protective immunity against *Chlamydia trachomatis*. *Immunology*. 2002;105(2):213-221.
- <span id="page-14-7"></span>46. Gondek DC, Olive AJ, Stary G, Starnbach MN. CD4<sup>+</sup> T cells are necessary and sufficient to confer protection against *Chlamydia trachomatis* infection in the murine upper genital tract. *J Immunol*. 2012;189(5):2441-2449.
- 47. Cunningham KA, Carey AJ, Timms P, Beagley KW. CD4+ T cells reduce the tissue burden of *Chlamydia muridarum* in male BALB/c mice. *Vaccine*. 2010;28(31):4861-4863.
- <span id="page-14-8"></span>48. Murthy AK, Li W, Chaganty BKR, et al. Tumor necrosis factor alpha production from CD8<sup>+</sup> T cells mediates oviduct pathological sequelae following primary genital *Chlamydia muridarum* infection. *Infect Immun*. 2011;79(7):2928-2935.
- <span id="page-14-9"></span>49. Vlcek KR, Li W, Manam S, et al. The contribution of *Chlamydia*specific CD8<sup>+</sup> T cells to upper genital tract pathology. *Immunol Cell Biol*. 2016;94(2):208-212.
- <span id="page-14-10"></span>50. Baker K, Rath T, Flak MB, et al. Neonatal fc receptor expression in dendritic cells mediates protective immunity against colorectal cancer. *Immunity*. 2013;39(6):1095-1107.
- <span id="page-14-11"></span>51. Megran DW, Stiver HG, Peeling R, MacLean IW, Brunham RC. Complement enhancement of neutralizing antibody to

the structural proteins of *Chlamydia trachomatis*. *J Infect Dis*. 1988;158(3):661-663.

- 52. Lausen M, Pedersen MS, Rahman NSK, et al. Opsonophagocytosis of *Chlamydia pneumoniae* by human monocytes and neutrophils. *Infect Immun*. 2020;88(7):e00087-20.
- <span id="page-14-0"></span>53. Caldwell HD, Kromhout J, Schachter J. Purification and partial characterization of the major outer membrane protein of *Chlamydia trachomatis*. *Infect Immun*. 1981;31(3):1161-1176.
- <span id="page-14-1"></span>54. Matheu MP, Sen D, Cahalan MD, Parker I. Generation of bone marrow derived murine dendritic cells for use in 2-photon imaging. *J Vis Exp*. 2008;17:e773.
- <span id="page-14-3"></span>55. O'Meara CP, Armitage CW, Harvie MC, Timms P, Lycke NY, Beagley KW. Immunization with a MOMP-based vaccine protects mice against a pulmonary *Chlamydia* challenge and identifies a disconnection between infection and pathology. *PLoS One*. 2013;8(4):e61962.

#### <span id="page-14-2"></span>**SUPPORTING INFORMATION**

Additional supporting information can be found online in the Supporting Information section at the end of this article.

**How to cite this article:** Armitage CW, O'Meara CP, Bryan ER, et al. IgG exacerbates genital chlamydial pathology in females by enhancing pathogenic CD8<sup>+</sup> T cell responses. *Scand J Immunol*. 2023;00:e13331. doi:[10.1111/sji.13331](https://doi.org/10.1111/sji.13331)